Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

A. Passaro,J. Wang,Y. Wang,S.-H. Lee,B. Melosky,J.-Y. Shih,J. Wang,K. Azuma, O. Juan-Vidal,M. Cobo, E. Felip,N. Girard,A.B. Cortot,R. Califano,F. Cappuzzo,S. Owen,S. Popat,J.-L. Tan, J. Salinas,P. Tomasini

Annals of oncology : official journal of the European Society for Medical Oncology（2024）

引用 6|浏览17

暂无评分

摘要

•Amivantamab–chemotherapy improved PFS and intracranial PFS versus chemotherapy.•Amivantamab–lazertinib–chemotherapy improved PFS and intracranial PFS versus chemotherapy.•Predominant AEs in the amivantamab-containing arms were hematologic, EGFR, and MET related.•MARIPOSA-2 is the first study to demonstrate improved PFS versus chemotherapy after disease progression on osimertinib.

查看译文

关键词

amivantamab,lazertinib,EGFR-mutated,NSCLC,post-osimertinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要